Module 3 2019

Key Points

• Should be based on the Target Product Profile (TPP) of the drug product

• This relates to quality, safety and efficacy

• Critical quality attributes (CQAs) of the drug product should be identified

• Provide scientific justifications for any claims made in the dossier

The Organisation for Professionals in Regulatory Affairs